OncoArendi is a partner in a €8.3 million Horizon 2020 EU grant awarded to international ‘PRECIOUS’
Read more here Press_Release_PRECIOUS.pdf
To learn more about the project, visit the EC website.
OncoArendi moves into new laboratories at the University of Warsaw
In relation to the above transition, OncoArendi management informs that as of April 1, 2016, the company headquarters have moved to:
OncoArendi Therapeutics Sp. z o.o.
Centrum Nauk Biologiczno-Chemicznych UW
Zwirki i Wigury 101
02-089 Warsaw Poland
OncoArendi Therapeutics announces selection of its first clinical development candidate
On October 9, 2015, OncoArendi Therapeutics announced that it selected OATD-01 as its clinical development candidate for the treatment of asthma. Submission of the Company's first Investigational New Drug ("IND") is expected by mid-2017.
OATD-01 is an orally active, non-steroidal small molecule which is a potent inhibitor of murine and human acidic mammalian chitinase (AMCase), one of the active chitinase enzymes. Based upon available information OATD-01 is thought to be the first chitinase inhibitor to enter development. Oral administration of OATD-01 has excellent pharmacokinetic characteristics in three species, with high bioavailability, low clearance and high volume of distribution. In addition, OATD-01 has good metabolic stability, moderate plasma protein binding and does not inhibit or activate human cytochrome P450 isozymes. The overall DMPK profile of OATD‑01 is consistent with the targeted once-a-day oral dosing in humans. OATD-01 is effective in two standard mouse models of asthma (ovalbumin and house dust mite), with anti-inflammatory activity superior to montelukast (Singulair), the only current oral asthma medicine that is used regularly. OATD-01 has low potential for off-target side effects as demonstrated by clean profile in the Diversity Profile™ (Eurofins, Cerep) consisting of 98 enzymes, ion channels and receptors, and no significant effect against the hERG channel. OATD-01 is negative in the Ames mutagenicity test.
Activities in support of IND-enabling pre-clinical testing of OATD-01 are already in progress with initiation of first in human studies expected during the second half of 2017. In parallel, OncoArendi Therapeutics is planning to carry out a supplementary profiling of OATD-01, including testing of in vivo efficacy in chronic models of asthma, translational study evaluation using human lung tissue, and biomarker experiments. OncoArendi Therapeutics AMCase inhibitors, including OATD-01, are protected by three pending patents covering three structurally different groups of compounds.
OncoArendi Therapeutics has broad interest and commitment to chitinase science with three distinct small molecule drug discovery programs directed against different chitinase family targets currently in progress. Potential therapeutic applications for compounds resulting from this R&D Chitinase Platform include treatment of numerous diseases with high unmet medical need, such as idiopathic pulmonary fibrosis (IPF), chronic obstructive pulmonary disease (COPD) and inflammatory bowel disease (IBD) as well as tropical diseases and some types of cancers.
OncoArendi Therapeutics receives another 20 mln PLN financing
The National Center for Research and Development (NCBR) announced results of its evaluation of project proposals submitted to the July call within the Priority I of the Smart Development Operational Program 2014-2020, Activity 1.1. “Enterprise R/D projects”, Action 1.1.1 „Industrial research and development for enterprises”. The proposals recommended for funding included the OncoArendi project entitled “Development of a first-in-class small molecule drug candidate for treatment of idiopathic pulmonary fibrosis through chitotriosidase inhibition.” This project is a continuation of the long term strategy of OncoArendi to develop anti-inflammatory small molecule therapies based on the Chitinase Platform. OncoArendi has received approx. 20 mln PLN co-financing from European Funds for the project with a budget of 25.5 mln PLN (approx. 6.5 mln USD). This funding should allow the company to advance development of the new Chit-1 inhibitor through phase I clinical trial. The project includes efficacy studies for the second indication in COPD.
OncoArendi Therapeutics receives over 22 mln financing
The National Center for Research and Development (NCBR) announced results of its evaluation of project proposals submitted to the May call within the Priority I of the Smart Development Operational Program 2014-2020, Activity 1.1. “Enterprise R/D projects”, Action 1.1.1 „Industrial research and development for enterprises”. Among 179 proposals submitted to this call, 34 were recommended for funding. Ranked third among all proposals was OncoArendi’s project entitled “Preclinical research and clinical trials of a first-in-class development candidate in therapy of asthma and inflammatory bowel disease.” This project is a key component of the OncoArendi strategic research area of development of anti-inflammatory small molecule therapies based on the chitinase family of targets (the so-called Chitinase Platform). OncoArendi has received over 22 mln PLN co-financing from European Funds for the project with a budget of 30 mln PLN (approx. 8 mln USD). This funding should allow the company to advance development of the new AMCase inhibitor up to Phase II clinical trials.
OncoArendi Therapeutics has entered into a global license agreement with Yale University
OncoArendi Therapeutics in a project co-financed from the European Funds under the Innovative Economy Operational Programme has progressed the earlier work to show in vivo efficacy of AMCase Inhibitors in two different animal models of human asthma. Having secured over $3M in public and private funding for continuing this work, OncoArendi Therapeutics plans to identify a development candidate within the next 6 months and progress its development to IND submission and Phase I clinical trials by early 2017. In its research and development activities OncoArendi continues to collaborate with the groups of Prof. Jack A. Elias at Brown University and of Prof. Jakub Golab at the Medical University of Warsaw.
Michał Sołowow invested in OncoArendi Therapeutics Sp. z o.o.
OncoArendi is a dynamically growing biotechnological company, which develops innovative anti-inflammatory and antitumor drugs with unique mechanisms of actions. Twelve million PLN obtained from Series A investors, with Michał Sołowow as leading investor, will allow the company to work on its key programmes for the next three years: potential asthma therapy and a group of new compounds stimulating the anti-tumour response of the human immune system. About 4 million Poles and 300 million people worldwide suffer from asthma with more and more children developing the disease. Currently used steroid therapies have severe side effects. At the same time every year cancer is diagnosed in more than 14 million patients and it remains the most frequent cause of death worldwide. In Poland both cancer incidents and death rate are the highest among European Union countries.
Apart from the company’s unique research programs and world leading position in the area of inhibitors of proteins called chitinases, investors were attracted to OncoArendi by its team of top medicinal chemists with many years of experience in pharmaceutical and biotechnology companies in the US, outstanding molecular biologists and successful managers with experience leading high-technology companies to IPO. Crucial for the investors was also The financial support, which the Company received from NCBR, was also important for investors, because it significantly lowers the risk of long term investment in scientific research.
OncoArendi is the first biotech investment for Michał Sołowow. This sector still developing in Poland. Financing research aimed at developing innovative drugs is very risky, but if successful, the potential return on investment may be great. Acquisitions of New drug candidates, which have already entered clinical trials, may be acquired by global pharmaceutical companies for hundreds of millions of dollars.
Investors and OncoArendi have joined forces to deliver to patients more effective and safer drugs than presently available therapies, along with company growth and substantial economic return.
Oncoarendi Therapeutics won over 25.5 million zloty
The aim of this project is to develop a conceptually novel therapeutic approach in cancer treatment – small molecule immune-modulators to knock-down the ability of tumors to escape immune surveillance.
The project was ranked second among twelve proposals recommended for funding and a total of one hundred and nine evaluated project proposals.
OncoArendi receives a grant of over 7 mln PLN for its lead drug discovery program
On June 2, 2014 OncoArendi received another grant for IP protection
Invitation to tender
OncoArendi Therapeutics has signed an exclusive agreement
OncoArendi Therapeutics has closed its angel investment round raising
OncoArendi has signed a contract agreement with the Polish Agency for Enterprise Development
The Nencki Institute of Experimental Biology has just signed
A patent application for the OAT-449
The contract was signed with the National Center for Research and Development
The project will run through September 2015.
Funding received for the first discovery program
OncoArendi was successful in securing 1,6M in public financing in an joint application with the Institute of Biophysics and Biochemistry, Polish Academy of Sciences and the International Institute for Molecular and Cell Biology for a project entitled "New drug candidates for targeted therapy of multiple myeloma".